James Carswell
Critical Care Medicine · Charleston, SCNPI 1720038805
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $143,225 of the $158,735 with a category attached, or 90.2%. GSK accounts for 85.0% of it on its own, with 45 other manufacturers making up the rest. Among critical care medicine clinicians in SC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 593 payments — averaging $267.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$135K
- Sanofi$16K
- AstraZeneca$1K
- Jazz Pharmaceuticals Inc.$1K
- Regeneron Healthcare Solutions, Inc.$560
- Harmony Biosciences LLC$488
- plus $5K from 40 others
Across 71 payments — averaging $4214.12 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$150K
- Sanofi US Services Inc.$43K
- Mallinckrodt Enterprises LLC$28K
- Jazz Pharmaceuticals Inc.$25K
- GSK$24K
- Mallinckrodt Hospital Products Inc.$14K
- plus $15K from 2 others
What the payments were for
- Speaking & faculty fees$143,22590%
- Travel & lodging$3,9783%
- Food & beverage$11,0537%
- Education$4620%
- Gifts$170%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRELEGY ELLIPTA$77,559
- DUPIXENT$20,809
- ANORO$10,035
- NUCALA$9,750
- TEZSPIRE$217
How this compares
$158,735 in reported general payments places this provider in the 95th percentile of 93 critical care medicine providers in South Carolina.
See all critical care medicine providers in South Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 360 | $311,159 |
| XywavSodium,calcium,mag,pot Oxybate | 12 | $238,631 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 36 | $136,701 |
| XolairOmalizumab | 30 | $123,849 |
| Dupixent SyringeDupilumab | 24 | $89,310 |
| Breo ElliptaFluticasone/Vilanterol | 128 | $74,040 |
| Dupixent PenDupilumab | 16 | $70,579 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 107 | $61,838 |
| NucalaMepolizumab | 14 | $57,447 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 70 | $52,562 |
| TezspireTezepelumab-Ekko | 12 | $51,369 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 57 | $39,285 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 29 | $22,844 |
| Spiriva RespimatTiotropium Bromide | 28 | $16,388 |
| Spiriva HandihalerTiotropium Bromide | 12 | $14,928 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Nucala, Incruse Ellipta | $134,875 | $514,481643 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid | $163 | $136,70136 claims |
| AstraZenecaBreztri Aerosphere, Tezspire, Symbicort | $1,182 | $109,601107 claims |
| Boehringer IngelheimStiolto Respimat, Combivent Respimat, Spiriva Respimat | $429 | $78,517114 claims |
| Axsome Therapeutics, Inc.Sunosi | $463 | $10,45612 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 93 critical care medicine providers in South Carolina.
Other critical care medicine in Charleston
- Charlton StrangeCharleston$205K
- Rahul ArgulaCharleston$186K
- Nicholas FoxCharleston$88K
- Christopher GilbertCharleston$44K
- Gregory SquiresCharleston$14K
- John MitchellCharleston$10K
- Luca PaolettiCharleston$5K
- Jennings NestorCharleston$5K
- Tatsiana BeikoCharleston$4K
- Stephen SexauerCharleston$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.